anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
1312670 Moulding apparatus M COPPOLA 26 June 1970 [26 June 1969] 31086/70 Heading B5A A rotary table moulding apparatus, e.g. for lipsticks, includes a number of moulds C spaced around the periphery of a table A rotated stepby-step relative to a stationary table 3; each mould comprises a part 18 attached to table A and a detachable part or cap 20 attached to a lever 24 secured to a head 32 pivotable about a shaft 34. A stem secured to the head carries a roller 40 engaging cam surfaces 44, 45 on the table 3 whereby the cap is removed from the part 18 of the mould to enable the moulded product to be ejected by a downwardly driven rod. Molten material is supplied to the moulds when in one position and the article is removed when the mould is in a second position. The periphery of the table A passes through a cooling chamber to solidify the molten charge. In the embodiment of Fig. 3 the moulded article is a lipstick and is pushed from the mould into a tubular receiver 56 pivotable about a horizontal axis 50 to transfer it from a lipstick receiving position to a horizontal position aligned with a lipstick casing F, F 1 , delivered from a hopper H and received into one of a series of peripheral grooves 88 in an intermittently driven drum 86. A plunger in the receiver is reciprocated by a crank via a linkage to feed the lipstick into a casing.
The interventions are designed to address the seven key self-management behaviours identified by the Association of American Diabetes Educations: (1) healthy eating, (2) being active, (3) monitoring, (4) taking medication, (5) problem solving, (6) reducing risk, and (7) healthy coping. In addition, the Chronic Care Model elements of self-management support and patient centered-care approach is embraced during the intervention process. The nursing care components provided to participants will be included (a) self-care management knowledge, (b) skill-based learning and problem solving, (c) participants' participation and engagement, (d) participants' in goal setting, and (e) coordinate care, involve participants to make decision.
PURPOSE:To control the precipitation of dregs of drink, drink medicine, etc. comprising a natural extracted solution, by using whey. CONSTITUTION:Whey obtained after the separation of curd in the preparation of cheese, etc. is added to a drink such as fruit juice, cocoa, tea, etc. comprising a natural extracted solution and a medicine such as a ginseng, etc. It is also effective in a carbon dioxide-containing drink.
1,135,783. Anticoagulants. CANADA PACKERS Ltd. 19 May, 1966 [20 May, 1965], No. 22377/66. Heading ASB. Anticoagulant compositions suitable for oral administration comprise heparin, or a heparinoid e.g. heparitin sulphate (heparin monosulphuric acid), or dextran sulphate in combination with at least one non-toxic physiologically acceptable absorption-enhancing sulphone having the formula R 1 R 2 SO 2  wherein R 1  and R 2  are selected from (a) alkyl and alkenyl of up to 12 carbon atoms; (b) aralkyl; (c) a cyclic structure wherein R 1  and R 2  together with the sulphur atom form a ring containing 4 or 5 carbon atoms. Examples of suitable sulphones include diethyl and di-n-propyl sulphone and sulpholane and sulpholene and their homologues and close analogues e.g. wherein one or more of the hydrogen atoms may be substituted by hydrocarbon radicals. The compositions may also contain water and may be in the form of a solution or suspension, or preferably may be encapsulated in a gelatin capsule which is enteric coated.
Subjects with progressive, non-functional advanced or metastatic thoracic, GI or pancreatic well-differentiated neuroendocrine tumors (NET) have few treatment options. The only FDA approved treatment regimen offers little response potential. In currently unpublished data with inhibitory immune checkpoint agents, patients with NET have shown promising clinical benefit. This therapy offers a novel approach to potentially provide long term benefit, but must be further explored. The safety profile of nivolumab plus ipilimumab is characterized by immune-related toxicities, such as diarrhea, rash, pneumonitis, liver toxicity, and endocrinopathies (Nivolumab, Ipilimumab Investigator's Brochures). The frequencies and intensities of these events in the combination are variable and depend on the specific doses and schedule used. In the dosing schedules selected, these events were mostly low grade and manageable with the use of corticosteroids. Nivolumab and ipilimumab combination therapy has shown improved efficacy over either agent alone in melanoma. Rationale for Single Arm Design This study will use a single arm open-label design. The objective of this study is to evaluate the objective response rate of combination nivolumab and ipilimumab in advanced, well-differentiated neuroendocrine tumors. Durability of response, and PFS will also be described.
The present disclosure discloses a composition comprising: (a) at least one sulphated galactose; and (b) at least one saccharide selected from a group consisting of disaccharide, trisaccharide, tetrasaccharide, pentasaccharide, and salts thereof. The present disclosure further discloses a weight percentage of the at least one sulphated galactose to be in a range of 15-90% with respect to the total sugar content. Further, the present disclosure discloses a use of the composition for protecting/treating plants from infection. Also provided is a use of the composition for protecting/treating animals from infection. The present disclosure discloses a use of sulphated galactose for protecting/treating plants from infection. Also provided is a use of sulphated galactose for protecting/treating animals from infection. The present disclosure also discloses a method for preparing the composition as described herein.
For patients in the PCA group, 200 mg of tramadol was placed in 100cc of 0.9% NaCl. Set to PCA device. A 50mg loading dose was administered 10 minutes before the patient was extubated. After extubating, a bolus dose of 20 mg was started, with a 30-minute lock-in time, and an infusion dose of 5mg/hour. The 4-hour maximum limit was set to 200 mg.
The study sought to systematically compare the expression of molecular markers in benign cutaneous lesions and squamous cell cervical carcinoma associated with HPV infection to better understand the pathophysiological mechanisms involved in HPV-related lesions and their progression to malignancy. We included 200 patients recruited from a gynecological clinic divided into two groups: 100 patients with positive HPV tests presenting with cutaneous lesions and 100 patients diagnosed with squamous cell cervical carcinoma and testing positive for HPV. The participants were selected to ensure diverse ethnic and demographic representation. The study utilized different statistical analyses, including Chi-square tests to assess associations between categorical variables and logistic regression to evaluate factors influencing lesion progression and compare marker expressions across different lesion types. The results indicated significant differences in the expression of specific molecular markers between cutaneous lesions and cervical carcinomas, highlighting distinct molecular pathways involved in HPV-related lesion development. Notably, markers such as p16, p53, and E-cadherin showed varying expression, suggesting their potential role in distinguishing between benign and malignant lesions. The findings emphasize the significance of molecular marker profiling in improving diagnostic and therapeutic strategies for HPV-related lesions. The differential expression of molecular markers can offer valuable insights into the pathogenesis of HPV-induced lesions and help develop targeted interventions to prevent malignant transformation. Further research is necessary to validate these markers in larger cohorts and diverse populations.
The knee joint has long been considered a closed system. The pathological effects of joint diseases on distant organs have not been investigated. Herein, our clinical data showed that post-traumatic joint damage, combined with joint bleeding (hemarthrosis), exhibits a worse liver function compared with healthy control. With mouse model, hemarthrosis induces both cartilage degeneration and remote liver damage. Next, we found that hemarthrosis induces the upregulation in ratio and differentiation towards Th17 cells of CD4+ T cells in peripheral blood and spleen. Deletion of CD4+ T cells reverses hemarthrosis-induced liver damage. Degeneration of cartilage matrix induced by hemarthrosis upregulates serological type II collagen (COL II), which activates CD4+ T cells. Systemic application of a COL II antibody blocks the activation. Furthermore, bulk RNAseq and single-cell qPCR analysis revealed that the cartilage Akt pathway is inhibited by blood treatment. Intra-articular application of Akt activator blocks the cartilage degeneration and thus protects against the liver impairment in mouse and pig models. Taken together, our study revealed a pathological joint-liver axis mediated by matrikine-activated CD4+ T cells, which refreshes the organ-crosstalk axis and provides a new treatment target for hemarthrosis-related disease. Intra-articular bleeding induces cartilage degradation through down-reulation of cartilage Akt pathway. During this process, the soluble COL II released from the damaged cartilage can activate peripheral CD4+ T cells, differention into Th17 cells and secretion of IL-17, which consequently induces liver impairment. Intra-articular application of sc79 (inhibitor of Akt pathway) can prevent the cartilage damage as well as its peripheral influences.
Ameluz will be applied to skin. This will be followed by a 30-minute incubation period. Subsequently, you will receive Red Light Treatment for 10 minutes. Post-treatment assessments will be performed and you will be given instruction on appropriate sun protection methods.
FIELD: medicine, veterinary science. ^ SUBSTANCE: invention concerns veterinary. The pharmaceutical composition for treating diabetes containing tripeptide Pro-Gly-Pro as an agent dissolved in such proportion that the amount of the intranasal tripeptide is 1 mg/kg of body weight. The method of treating diabetes involves the intranasal introduction of the described composition. ^ EFFECT: invention allows faster recovery, lower toxic effects without deterioration of clinical effectiveness, and simplified introduction procedure. ^ 2 cl, 2 tbl, 3 ex
This multi-center, open-label, randomized trial aims to compared the efficacy and safety profiles of sodium alginate oral suspension (50mg/ml) 20ml at bedtime with that of esomeprazole (40mg/tablet) 1 tablet once daily for the treatment of erosive GERD patients in Taiwan. Patients will be enrolled into study if they are diagnosed as GERD (grade A\~D); with history of heartburn (or regurgitation) for ≥ 3 months before entering study; with history of GERD-related sleep disturbances for ≥ 1 month before entering study; with nighttime heartburn (or regurgitation) graded as moderate, or severe, on ≥ 3 nights in the last 7 days of screening period; with GERD-related sleep disturbances on ≥ 3 nights in the last 7 days of screening period; with the global PSQI score \>5; and have signed the informed consent. Patients will be excluded if they are diagnosed as non-erosive GERD, Barrett's esophagus or esophageal stricture; with any conditions other than GERD that could be the primary cause of sleep disturbance; with active esophageal, gastric or duodenal ulcers; with history of esophageal, gastric or duodenal surgery; with active cancers of any kind; female patients who are pregnant or lactating; who were allergy to any of the study drugs; taking a proton pump inhibitor (PPI) within 7 days, or any prokinetic agent, H2-blocker, alginate preparations or antacid within 2 days before screening; with a history of drug addiction or alcohol abuse within the past 12 months; or with any other conditions or diseases that investigator considers it is not appropriate to enter the study. The primary efficacy endpoint is the percentage of patients with relief of nighttime heartburn (or acid regurgitation). The secondary efficacy endpoints are percentage of patients with complete resolution of nighttime heartburn (or regurgitation); percentage of patients with relief of GERD-related sleep disturbance; percentage of patients with complete resolution of GERD-related sleep disturbance; percentage of nights without nighttime heartburn (or regurgitation) over treatment period; change from baseline of the Pittsburgh Sleep Quality Index questionnaire total score (global PSQI score) at the end of study; and change of the percentage of patients with relief of nighttime heartburn (or acid regurgitation) at post-treatment visit (V4) as compared to final visit (V3) in test group (Nexium plus Alginos). The safety endpoint is incidence of adverse events. This study aims to prove that sodium alginate plus esomeprazole is superior to esomeprazole alone in relieving nighttime reflux symptoms and sleep disturbance in erosive GERD patients.
Standard Clinical Care Plus 8-week Isometric Lingual Exercise Regimen. The isometric tongue exercises will be completed using the Madison Oral Strengthening Therapeutic (MOST) device. Baseline maximum lingual pressure will be obtained at the anterior and posterior sensors independently by gathering two sets of data (3 MOST device trials) at each site (anterior and posterior) that differ by less that 5%. During week one of the regimen, the target value of each repetition will be 60% of the maximum baseline pressure. For the remaining seven weeks of the program, the target value will be increased to 80% of the maximum. At weeks three, five, and seven, the baseline will be re-measured by phone and the 80% target value re-calculated.
Rasuvo is a manually-triggered auto-injector intended for subcutaneous use under the guidance and supervision of a physician.

Patients may self-inject with Rasuvo if a physician determines that it is appropriate, if they have received proper training in how to prepare and administer the correct dose, and if they receive medical follow-up, as necessary.

Rasuvo is injected once weekly. The patient must be explicitly informed about the once weekly dosing schedule. It is advisable to determine an appropriate fixed day of the week for the injection.

Visually inspect Rasuvo for particulate matter and discoloration prior to administration. Do not use Rasuvo if the seal is broken.

Handle and dispose of Rasuvo consistent with recommendations for handling and disposal of cytotoxic drugs1.
Placebo group: 30 minutes to earn pulse, I, 1, and dripping Yunmi gave 100mL placebo (sodium chloride injection). It is administered twice a day for 1 to 2 hours, and the pattern is transferred to about 7 people, that is, about 14 times in total.
Current medication adherence interventions are minimally effective, which results in higher rates of morbidity and mortality for 45 million US adults who have hypertension and low adherence. This feasibility randomized controlled trial seeks to understand the efficacy of reminders and monitoring in the form of a mobile phone application vs usual care on medication adherence as well as the feasibility of the intervention and study procedures. This study will compare participants who use a mobile phone app that notifies them when to take their medications (intervention group) to participants who do not get assigned the app (control group) for 30 days. Participants will receive an electronic monitoring cap (i.e. a Medication Event Monitoring System (MEMS) cap) to monitor when they take their antihypertensive medications while they are in the study. Both groups will also receive the usual care, which will include giving participants a pamphlet about taking their medications. The long-term goal of this work is to improve antihypertensive medication adherence and to decrease morbidity and mortality. The objective of this application is to test the efficacy of the app based reminders and feedback. The hypothesis driving this research is that the intervention will be more effective than the usual care. The specific aims are as follows:

Aim 1. Compare the efficacy of the app based reminders and feedback with usual care for the primary outcome of medication adherence in 40 adults with hypertension and low adherence.

Aim 2. Conduct a robust process evaluation to guide intervention improvements, dissemination, and implementation in a diverse sample.

The hypothesis will be tested for two specific aims in 40 adults (20 control, 20 intervention) with hypertension and low adherence. For these aims, the study will be conducted as a phase II single-blind, parallel-group, randomized controlled trial with diverse adults with hypertension over 30 days. Participants will answer surveys about their demographics, knowledge about hypertension, and their medication adherence. They will then be randomized and either be given the standard of care or standard of care plus the intervention (app-based reminders and feedback). The intervention includes a brief training session on downloading and using the medication reminder app. Across arms, Participants will track their medication adherence for 30 days using the MEMS cap. After the 30 days, participants will take surveys about their adherence and knowledge about hypertension and have a brief exit interview with a member of the research team to talk about their experience and debrief them about the study.
Inject the dose (over 5-10 seconds is normally recommended) into the antecubital vein, after taking precautions to avoid extravasation. A syringe, filled with AK-FLUOR®, may be attached to transparent tubing and a 23 gauge butterfly needle for injection. Insert the needle and draw the patient's blood to the hub of the syringe so that a small air bubble separates the patient's blood in the tubing from the fluorescein. With the room lights on, slowly inject the blood back into the vein while watching the skin over the needle tip. If the needle has extravasated, the patient's blood will be seen to bulge the skin and the injection should be stopped before any fluorescein is injected. When assured that extravasation has not occurred, the room light may be turned off and the fluorescein injection completed. Luminescence usually appears in the retina and choroidal vessels in 7 to 14 seconds and can be observed by standard viewing equipment.

Reduction in dose from 500 mg to 200 mg of AK-FLUOR® 10% may be appropriate in cases when a highly sensitive imaging system e.g., scanning laser ophthalmoscope is used.
A method for treating a malignant tumor in a patient identifies tumor cells using a logical AND operation on antigens on the surfaces of the tumor cells. First and second antigens are determined to be present on the tumor cells. A first medication including a first antibody and a second antibody is administered to the patient. The first antibody is linked to a first dock, and the second antibody is linked to a second dock. In the patient's body, the first antibody binds to a first antigen, and the second antibody binds to a second antigen. After the elapse of a first predetermined interval, a second medication is administered to the patient. The second medication forms a structured binding site when the second medication simultaneously binds to both the first dock and the second dock. After the elapse of a second predetermined interval, a third medication is administered to the patient. The third medication binds only to the structured binding site and activates immune cells of the patient.
The invention discloses a composite medicine for treating diabetes and a preparation method thereof. The composite medicine is prepared from 20-60g of hairy holly root, 20-60g of wild chrysanthemum, 10-20g of scutellaria, 10-20g of phellodendron, 10-20g of coptis, 10-15g of astragalus, 10-15g of trichosanthes root, 10-30g of fresh rehmannia, 10-15g of acanthopanax, 10-15g of ophiopogon and 8-10g of licorice. The preparation method is as follows: the medicines are weighed according to a formula and all crushed into rough powder; the rough powder of the medical raw matreials is immersed in a dilute alcohol solution containing 40% ethanol for 1 hour; the rough powder is heated with the dilute alcohol solution containing 40% ethanol; the liquid level of the dilute alcohol solution is kept higher than the raw material chemical powder, the temperature is kept at 60-80 DEG C, extraction is performed thrice for 4 hours, the medical liquid is extracted via concentration, meanwhile, the ethanol is recovered. The pharmacy steps can be performed according to common oral solid agent, the prepared oral solid preparation is converted into the total amount of a crude drug, and at least 21g of the crude drug is taken every day. Water decocting liquid equivalent with the glossy ganoderma and Chinese yam in amount is used as an initiator taken along with the composite medicine. A period of treatment includes 30 days. The composite medicine is continuously taken for three periods of treatment, and the cure rate reaches over 95 percent.
The invention relates to compounds for use in the treatment of allergic diseases including juvenile asthma and eczema. The compounds can inhibit IgE mediated reaction to major environmental and occupational allergens. They can also have a prophylactic effect against allergic disease by preventing allergic sensitisation to environmental and occupational antigens when administered to at-risk individuals (e.g. those at genetic risk of asthma, and those exposed to occupational allergens in the workplace). The compounds of the invention can also be useful for inactivation or attenuation of the allergenicity of allergens in situ. The invention provides novel compounds and ligands per se, pharmaceutical compositions containing the compounds, processes for producing the compounds and pharmaceutical compositions, and methods for using the compounds and compositions in treatment or prophylaxis of IgE mediated allergic diseases and in inactivation or attenuation of allergens in situ. The invention also provides means for the reducing or destroying the viability of allergy-causing organisms.
Photodynamic therapy (PDT) is a cancer treatment strategy that utilizes photosensitizers to convert oxygen within tumors into reactive singlet oxygen (1O2) to lyse tumor cells. Nevertheless, pre-existing tumor hypoxia and oxygen consumption during PDT can lead to an insufficient oxygen supply, potentially reducing the photodynamic efficacy. In response to this issue, we have devised a pH-responsive amphiphilic triblock fluorinated polymer (PDP) using copper-mediated RDRP. This polymer, composed of poly(ethylene glycol) methyl ether acrylate, 2-(diethylamino)ethyl methacrylate, and (perfluorooctyl)ethyl acrylate, self-assembles in an aqueous environment. Oxygen, chlorine e6 (Ce6), and doxorubicin (DOX) can be codelivered efficiently by PDP. The incorporation of perfluorocarbon into the formulation enhances the oxygen-carrying capacity of PDP, consequently extending the lifetime of 1O2. This increased lifetime, in turn, amplifies the PDT effect and escalates the cellular cytotoxicity. Compared with PDT alone, PDP@Ce6-DOX-O2 NPs demonstrated significant inhibition of tumor growth. This study proposes a novel strategy for enhancing the efficacy of PDT.
Population We will recruit 59 males and females age \> 18 being seen in the NYU Langone Center for Prevention of Cardiovascular Disease (4F). Participants have cardiovascular disease or cardiovascular disease risk factors.